National Alliance on Mental Illness
page printed from http://www2.nami.org/
(800) 950-NAMI; email@example.com
ACCESS TO MEDICATION TASK FORCE REPORT AND RECOMMENDATIONS TO THE NAMI BOARD OF DIRECTORS
The NAMI Board of Directors has charged NPRI’s Access to Medications Task Force to examine the available evidence on trends, practices and alternatives to limit access to medications for people with severe mental illness, and to provide policy guidance on this issue to the Board. This report to the Board provides a comprehensive strategy for addressing threats to access to medications.
The Task Force identified the following guidelines, which served as a basis for the policy recommendations to the Board:
The policy recommendations fall into three major categories: federal, state and community and are arranged by legislative, regulatory, legal and evidence-based initiatives.
The Task Force also recommended a set of deliverables that NAMI should develop to facilitate the actions proposed in this report to the Board.
States face increasingly difficult fiscal situations. State tax revenues are falling more sharply than they have at any time in the past ten years and Medicaid health care costs are skyrocketing. Spending on prescription drugs is the fastest growing proportion of Medicaid spending.
While spending on prescription drugs accounts for around 10 percent of total spending on health care in the U.S., recently, prescription drug costs have contributed disproportionately, to the sharp upturn in overall health care costs. As a result, prescription drugs are consuming a growing share of Medicaid dollars, accounting for 10 percent of Medicaid spending. Moreover, Medicaid spending on prescription drugs has increased 18 percent annually for the last three years.
Increased spending on prescription drugs for the Medicaid population is being driven by four factors:
To control pharmaceutical spending, a number of states have adopted or are considering restrictions on access to certain types of more expensive medications, including psychotropic medications, in their Medicaid programs. States will be attempting to improve their capacity to control drug costs in the following ways:
All of these options are being given serious consideration by states as they struggle to control Medicaid expenditures on prescription drugs. Prior authorization proposals have appeared in legislation, appropriations bills and regulations. They pose significant threats for Medicaid recipients with mental illnesses trying to access medications prescribed by their treating physician.
It is current NAMI policy that decisions regarding specific medications prescribed to persons with severe mental illness should be based on the clinical judgments of treatment providers, not on economic factors. NAMI strongly opposes measures that limit access to treatment with psychotropic medications such as atypical antipsychotics and selective serotonin reuptake inhibitors.
In response to the developing threats to access to medications for people with severe mental illness, the NAMI Policy Research Institute’s Access to Medications Task Force was created and charged by the NAMI Board of Directors to examine the available evidence and provide policy guidance on this issue to the NAMI Board, NAMI’s grassroots advocates, and policymakers.
The Access to Medications Task Force met on December 9, 2002 to:
An agenda and supporting material for the task force meeting are included in the enclosed binder for your information.
Development of Guidelines
To organize its work, the Access to Medication Task Force developed guidelines for its deliberations. The policies that flow from these guidelines were based on extensive discussions and they address both short and long term issues as well as the needs and interests of NAMI’s members at federal, state and local levels.
Cost containment and stringent utilization controls often hurts access. Prescription drugs are essential to the recovery and continuing health of most people with severe mental illness. Ensuring access to the most effective psychotropic medications is essential.
Pharmaceutical companies must bring drugs to the market place at reasonable and affordable prices. At the same time, state agencies must provide sufficient funding to guarantee access to potentially cost-saving medications and must avoid regulations that simply shift healthcare costs.
Appropriate medication is as important to recovery from mental illnesses as it is for recovery from somatic illnesses. It offers the same alternative to more expensive care and treatment in both cases. If policymakers choose to do less for fewer people with mental illness, the cost of this neglect will not only be counted in human suffering, it will reappear in other areas of their budgets and/or in other levels of government.
Policymakers should weigh the costs of any strategy being considered against the anticipated benefits. Medicaid programs must measure the costs and health consequences and identify the risks inherent in a strategy. Cost containment and accountability must go hand in hand.
Rising pharmacy costs must be understood as part of the larger picture: dramatic reductions in long-term hospitalizations and criminalization result from access to effective medication, comprehensive outpatient treatment and timely short term inpatient treatment. We need to ensure that people with mental illnesses have adequate medications so fewer people end up being hospitalized longer than necessary or inappropriately incarcerated.
The mission of an effective patient care system is to deliver long-term value to the patient and society. Improving clinical quality by using evidence-based prescribing practices may require short-term investments and garner long-term savings.
It is very likely that using prior authorization programs along with other cost controls will reduce the medication compliance of people with severe mental illness. Previous implementation of multiple cost containment programs led to a significant number of persons with severe mental illness not receiving their medications. Barriers to appropriate care should be avoided. If individuals are denied access to medications, adverse events or outcomes should be reported by a physician charged with that responsibility. We believe this requirement is consistent with evidence-based health care practice.
Will advances in the pharmaceutical treatment of mental illness add to overall health care costs or yield savings as they supplant or reduce the need for other costly treatments? Patients should receive care based on the best available scientific knowledge. Cost control paradigms may reduce pressure on specific budget line items and they may be designed to minimize access concerns but they do not and are not designed to ensure quality care.
Access to psychotropic medications should not vary from state to state or from clinician to clinician because of cost containment decisions made by policymakers. Policymakers should base their decisions on the best available data from research on the cost benefit of the new generation of psychotropic medications. The Task force believes that access to medications should focus on a disease management approach to treatment.
Recommendations of the Access to Medications Task Force
The Task Force recommends that NAMI pursue the following strategies to ensure open access to medications in the current budget deficit environment. They should be seen as an integrated, comprehensive approach to addressing the needs and interests of the people we serve.
NAMI Policy Template
Legislative Regulatory Legal Evidence-Based
1. Support an Increase in FMAP
The federal government reimburses states for a substantial portion of their Medicaid costs. The Medicaid budget problems that states are experiencing are being exacerbated by reductions in federal Medicaid matching payments to some states. These payments are based on the "Federal Medical Assistance Percentage" or FMAP. The FMAP is determined by historical economic data. The current FMAP rates are based on data from years prior to the recession, placing a number of states in the position of having to fund their Medicaid programs with fewer federal dollars at a time when states are facing record state revenue shortfalls.
Realizing the service, infrastructure, and community economic impacts of the loss of federal funds if states cut back on their Medicaid spending, governors are aggressively supporting initiatives in Congress that will increase the federal match rates. Governors are also aware that there are serious implications regarding the safety of patients, cooperation of unions and loss of accreditation for Medicaid funds as state hospital staff cuts reach dangerous levels. Proponents of an FMAP increase contend that increased federal support will temper the need for drastic cuts in Medicaid programs.
NAMI should support congressional legislative efforts to increase FMAP in 2003, and work closely with the National Governors’ Association, Association of County Commissioners and Association of State Legislators as they work to increase federal Medicaid matching rates.
NAMI should closely monitor and support appropriate, emerging legislative initiatives to expand prescription drug coverage for Medicare beneficiaries. State pressure to control prescription drug spending will mount in the absence of a Medicare drug benefit. Many states must pay the expense of drug assistance programs for Medicare beneficiaries who do not have incomes low enough to qualify for Medicaid. They must also provide the state match for dually eligible recipients under Medicaid. The federalization of prescription drug expenses for these groups through the provision of a Medicare drug benefit has profound implications for state budgets and for the Medicaid program.
3. Support System-Wide Health Care Reform
The Access Task Force supports systemic health care reform to address the coverage, cost and quality problems in the health care delivery and financing system. NAMI should monitor systemic health care reform initiatives and support those that lead to better access to the most effective treatments. NAMI should participate in appropriate hearings and meetings addressing mental illness system reform and health care system reform. These two initiatives are inextricably intertwined.
Specifically, as a part of mental illness system reform, an information and tracking system should be established to support officials (e.g., a physicians), who are responsible, for monitoring individuals served and individuals denied service. It is critically important that a risk management type-officer be held accountable for monitoring and keeping appropriate records, otherwise reform efforts will be slowed. There must be better data collection processes at the state level, with federal oversight, so that a reasonable evaluation of the system of care can occur.
The President’s New Freedom Commission should address these issues in their final report.
NAMI should continue to press the Center for Medicaid and State Operations within the Centers for Medicare and Medicaid Services, to provide written guidance to state directors advising them of both their legal authority to create carve outs for medications for severe mental illnesses and the policy justification for such a measure. We believe that such guidance is consistent with federal Medicaid law and the current Administration’s policy with respect to access to treatment for people with disabilities.
NAMI supports increased research budget allocations to the National Institute of Mental Health. That research will develop a better understanding of access to services and treatment as well as the potential impact of the new generation of psychotropic medications. It would enable NAMI and other advocates to identify evidence-based practices that should shape public policy recommendations.
NAMI also supports increased funding for the Agency for Healthcare Research and Quality (AHRQ) initiatives that translate research into evidence-based practices. AHRQ should sponsor research on newer psychotropic medications compared to older medications, so patients receive medical care based on the best available scientific knowledge.
NAMI should monitor the TMAP initiative (see below) to determine if its protocols can lead to more effective and more cost-effective, prescribing practices.
1. Exemption of Psychotropic Medications
NAMI should promote and develop model language on carve-outs for anti-psychotic, anti-depressant, anti-anxiety and anti-convulsant medications as a starting point in discussions with state officials. The language should include a narrower carve-out like "anti-psychotic medications only," which should be considered only as a last resort, when a broader approach is not politically or economically achievable.
Advocates should emphatically oppose the use of fail-first provisions prior to authorization of state-of-the-art psychiatric medications.
NAMI must make it clear, in the appropriations process, that adequate funding of the state’s mental health care system is critical to ensure the health of the state’s citizens and communities. People with severe mental illness are the most vulnerable consumers – removing access to treatment is life threatening and provides no cost savings to the state over the long term.
Adequate funding and support of a strong mental health system and Medicaid program in every state must be one of NAMI’s highest priorities. The Task Force supports the development of a tracking system that would identify which individuals are or are not served. It is important to be able to document that our nation’s failure to provide adequate services for children and adults with mental illnesses has resulted in a crisis for schools, families, communities, and the states.
To further influence policy on access, NAMI advocates should arrange meetings with state Medicaid officials and officials in the executive branch, as well as with state policymakers and their staffs.
3. Pharmaceutical Pricing
The Task Force supports research and development efforts that support the development of new and effective medications. However, NAMI must not support pricing practices which make these same medications inaccessible to mentally ill people who depend on them. NAMI should monitor efforts on the part of pharmaceutical companies to not only contain but also reduce costs and to bring to market affordable medications. NAMI should monitor efforts by states to contain the cost of medications through more efficient purchasing arrangements that control the rate of escalation in prescription drug costs without harming access to medications.
Additional advocacy efforts should insist on procedures to protect Medicaid recipients with severe mental illness from harm.
The following actions are recommended:
A person, ideally a physician, should be appointed by the governor to see that all individuals served or denied care are tracked and that all adverse events are reported in a timely and pubic manner.
NAMI should work with broad-based coalitions of consumers, providers, legal rights groups, other health care advocacy organizations, and other appropriate groups to support such initiatives. Establishing short-term broad-based coalitions with interest groups who have similar objectives regarding access to prescription drugs can enhance NAMI’s effectiveness on the access issue.
NAMI should encourage the use of clinically tested medication algorithms to ensure the utilization of evidence-based medication practices. The Texas Medication Algorithm Project (TMAP) has produced treatment algorithms (including prescription drug therapy) for three serious mental illnesses – schizophrenia, major depressive disorder and bipolar disease. The paradigm has been adopted in other states. NAMI should support the continued development and evaluation of the efficacy of TMAP as an alternative to Medicaid cost containment strategies.
Advocates should contact their county commissioners, mental health directors and other local stakeholders to collaborate in engaging state Medicaid agencies on the access issue.
2. Work the Media
Advocates should contact the media’s health care reporters to discuss the potential implications of impeding access to prescription drugs.
Deliverables Requested by the Task Force
The NAMI Policy Research Institute has recently developed a comprehensive and integrated set of products (fact sheets, bulletins, alerts, sample letters to legislators and editorial boards, op-eds) to enable advocates to effectively engage state policymakers and other stakeholders on the access issue. The Task Force requested that the Institute develop the following information to aid in the efforts of advocates:
The Task Force believes that to ensure that people with severe mental illness have open access to critically necessary medications, NAMI and other advocates should use the strategies and tools outlined in this report to the Board. Advocates must work with policymakers and through appropriate channels to ensure that limited public dollars are used in the most effective way to protect access to the most effective treatments for people with severe mental illnesses. The next few years will be the most challenging mental health advocates have ever faced. We will need a comprehensive and coordinated effort to prevent long term damage to vulnerable people and an already inadequate system of care.